You need to enable JavaScript to run this app.
Recon: Pfizer Pays $250M to License Akcea Antisense Drug; Opioid Victims to Sit on Purdue Bankruptcy Committee
Recon
Michael Mezher
ReconMichael Mezher
ReconMichael Mezher